Cargando…
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
PTC596 is an investigational small-molecule tubulin-binding agent. Unlike other tubulin-binding agents, PTC596 is orally bioavailable and is not a P-glycoprotein substrate. So as to characterize PTC596 to position the molecule for optimal clinical development, the interactions of PTC596 with tubulin...
Autores principales: | Jernigan, Finith, Branstrom, Arthur, Baird, John D., Cao, Liangxian, Dali, Mandar, Furia, Bansri, Kim, Min Jung, O'Keefe, Kylie, Kong, Ronald, Laskin, Oscar L., Colacino, Joseph M., Pykett, Mark, Mollin, Anna, Sheedy, Josephine, Dumble, Melissa, Moon, Young-Choon, Sheridan, Richard, Mühlethaler, Tobias, Spiegel, Robert J., Prota, Andrea E., Steinmetz, Michel O., Weetall, Marla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398121/ https://www.ncbi.nlm.nih.gov/pubmed/34315764 http://dx.doi.org/10.1158/1535-7163.MCT-20-0774 |
Ejemplares similares
-
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma
por: Maeda, Aya, et al.
Publicado: (2018) -
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
por: Branstrom, Arthur, et al.
Publicado: (2022) -
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
por: Weetall, Marla, et al.
Publicado: (2016) -
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
por: Nishida, Y, et al.
Publicado: (2017) -
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells
por: Nagai, Yurie, et al.
Publicado: (2021)